UPDATE: Compugen Signs Novartis to Multimillion Dollar LEADS License | GenomeWeb

NEW YORK, Aug. 2 – Compugen has licensed its LEADS computational biology platform to Novartis, the company announced on Thursday.

The deal, which will run for one year with the option for Novartis to extend two additional years, also includes a proprietary DNA chip design to represent Novartis’ transcriptome database. The deal is worth a "few million dollars" Compugen CEO Mor Amitai told GenomeWeb.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."